Castle Biosciences CSTL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$12.83M+46.9% | -$24.16M-97.4% | -$12.24M-29.3% | -$9.47M-86.7% | -$5.07M-128% | ||
| $14.94M-63.4% | $40.77M-4.7% | $42.76M+0.6% | $42.49M+0.2% | $42.42M+165% | ||
| $44.49M-3.1% | $45.89M-0.1% | $45.93M-2.0% | $46.85M-4.0% | $48.82M-3.0% | ||
| -$5.58M+12.0% | -$6.34M— | —— | —— | —— | ||
| -$13.17M-91.5% | -$6.88M-4,267% | $165K-97.4% | $6.33M-53.4% | $13.6M+7.6% | ||
| $3.64M+69.7% | $2.14M+2.0% | $2.1M+495% | $353K+144% | -$796K-512% | ||
| $5.67M+83.3% | $3.1M+22.6% | $2.53M+344% | -$1.03M+69.0% | -$3.34M+23.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$342K+15.3% | -$404K— | —— | ||
| —— | —— | $3.88M+1,130% | $315K+136% | -$870K-257% | ||
| -$921K+27.8% | -$1.28M+14.5% | -$1.49M+13.6% | -$1.73M-10.3% | -$1.57M-21.4% | ||
| $48.25M-25.0% | $64.35M+4.2% | $61.78M-1.1% | $62.49M-4.8% | $65.67M+1.2% | ||
| $43.74M+21.4% | $36.02M-1.1% | $36.4M+30.3% | $27.95M+16.9% | $23.91M-15.6% | ||
| $195.42M+3.6% | $188.71M-5.0% | $198.63M+7.2% | $185.37M-4.2% | $193.41M-6.0% | ||
| —— | —— | —— | —— | $0— | ||
| $43K-4.4% | $45K-4.3% | $47K+46.9% | $32K+45.5% | $22K+22.2% | ||
| —— | —— | —— | —— | $5.57M— | ||
| —— | $2.11M+33.3% | $1.59M+50.0% | $1.06M+100% | $528.5K— | ||
| —— | —— | —— | —— | —— | ||
| $2.51M+13.8% | $2.21M+353% | $487K-75.4% | $1.98M+0.6% | $1.97M-2.3% | ||
| $113K-1.7% | $115K+0.9% | $114K+6.5% | $107K+23.0% | $87K-10.3% | ||
| $15.74M+35.0% | $11.66M+9.3% | $10.67M-1.0% | $10.78M-0.2% | $10.8M+23.3% | ||
| -$10.54M-49.3% | -$7.06M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3.24M-23.3% | $4.22M-17.7% | $5.12M-12.7% | $5.87M-8.6% | $6.42M-3.9% | ||
| —— | —— | —— | —— | -$1.01M-282% | ||
| —— | —— | —— | —— | —— | ||
| -$921K+27.8% | -$1.28M+14.5% | -$1.49M+13.6% | -$1.73M-10.3% | -$1.57M-21.4% | ||
| -$1.32M+3.6% | -$1.37M-2.7% | -$1.34M-2.1% | -$1.31M+6.8% | -$1.4M-6.2% | ||
| —— | —— | —— | —— | —— | ||
| $883K+126% | $391K+279% | -$218K-169% | -$81K+82.2% | -$454K-73.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$342K+15.3% | -$404K— | —— | ||
| —— | —— | —— | —— | $5.57M— | ||
| —— | —— | —— | —— | $0— | ||
| $43K-4.4% | $45K-4.3% | $47K+46.9% | $32K+45.5% | $22K+22.2% | ||
| $113K-1.7% | $115K+0.9% | $114K+6.5% | $107K+23.0% | $87K-10.3% | ||
| $2.71M+12.3% | $2.42M+2.9% | $2.35M-13.4% | $2.71M-5.2% | $2.86M-4.0% | ||
| —— | —— | —— | —— | —— | ||
| -$921K+27.8% | -$1.28M+14.5% | -$1.49M+13.6% | -$1.73M-10.3% | -$1.57M-21.4% | ||
| —— | —— | —— | $171K-34.7% | $262K+20.2% | ||
| $4.52M-84.0% | $28.33M+11.6% | $25.38M-26.5% | $34.54M-17.3% | $41.75M+14.3% | ||
| $4.52M-84.0% | $28.33M+11.6% | $25.38M-26.5% | $34.54M-17.3% | $41.75M+14.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Castle Biosciences generate?
- Castle Biosciences (CSTL) generated $48.3M in operating cash flow over the trailing twelve months.
- What is Castle Biosciences's free cash flow?
- After $43.7M of capital expenditures, Castle Biosciences's free cash flow was $4.5M over the trailing twelve months, down 89.2% year over year.
- Where does Castle Biosciences's cash flow data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
